Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas.

ABSTRACT:

Aims

Treatment of prolactinomas with ergoline dopamine agonists can be complicated by intolerance and resistance. This study investigated the pharmacokinetics and pharmacodynamics of the nonergot dopamine agonist ropinirole, to assess its therapeutic potential as a novel therapy for prolactinomas.

Methods

Five female subjects with prolactinomas participated in this dose-response study. Subjects received up to three doses of ropinirole (0.5, 1.0 and 2.0 mg), each on separate occasions. Frequent blood samples for prolactin and ropinirole were collected for 24 h following drug administration. Data were analysed using noncompartmental and compartmental pharmacokinetic-pharmacodynamic (PKPD) techniques.

Results

Seven 24-h curves revealed increased systemic drug exposure wi

SUBMITTER: Liu S 

PROVIDER: S-EPMC6339972 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature